Lataa...

Rebound-Associated Vertebral Fractures Two Months After a Missed Dose of Denosumab

Introduction: Denosumab, an anti-resorptive medication approved for treatment of osteoporosis, increases bone mineral density and reduces fracture risk. Discontinuation of treatment is associated with bone turnover rebound and reduced bone mineral density. We report a case of a woman without prior h...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Endocr Soc
Päätekijät: Caseja, Ahl Jeffrey, Abdullah, Najwa, Nakhle, Samer
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2021
Aiheet:
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8090346/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.443
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!